Browse
Submit Data
Databases
API
Help

Dataset Information

5 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

ABSTRACT: The purpose of this study is to determine the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) (or the highest protocol-defined dose level in the absence of establishing an MTD) of ibrutinib in combination with pembrolizumab in participants with advanced, refractory colorectal cancers.

DISEASE(S): Colorectal Carcinoma,Colon Disease,Colon Cancer,Colorectal Cancer,Colorectal Neoplasms,Colonic Diseases

PROVIDER: 2258148 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

Project description:To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment.

| 2294936 | ecrin-mdr-crc

NCIC CTG MA.22 phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer on 2-weekly or 3-weekly schedules

Project description:This phase I/II neoadjuvant trial determined maximally-tolerated doses (MTD), dose-limiting toxicities (DLT), response-to-therapy, and explored the role of new response biomarkers. The combination regimens were delivered with acceptable toxicity, good clinical response, inducing changes in tumor RNA content and integrity. Pre-treatment gene expressions impacted clinical response, including several near 17q12, which with ERBB2, may better identify chemoresponsiveness.

2015-11-11 | GSE66999 | GEO

First-in-human study of the novel fibroblast activation protein-targeted 4-1BB agonist RO7122290 in patients with advanced solid tumors

Project description:This first-in-human (FIH) study evaluated RO7122290, a novel, bispecific fusion protein carrying a split trimeric 4-1BB (CD137) ligand and a fibroblast activation protein-α (FAP) binding site that effectively co-stimulates T cells for improved tumor cell killing in FAP-expressing tumors. Patients with advanced and/or metastatic solid tumors received escalating weekly intravenous doses of RO7122290 as a single agent (n = 65) or in combination with 120mg fixed dose of the anti-PD-L1 antibody atezolizumab given every 3 weeks (n = 50), across a tested RO7122290 dose range of 5 to 2000 mg and 45 to 2000 mg, respectively. Three dose-limiting toxicities (DLTs) were reported, two at different RO7122290 single-agent dose levels (grade 3 febrile neutropenia, grade 3 cytokine release syndrome) and one for the combination (grade 3 pneumonitis). No maximum tolerated dose (MTD) was identified. The pharmacokinetic (PK) profile of RO7122290 was typical of target-mediated drug disposition. The observed modulation of proximal and distal pharmacodynamic (PD) biomarkers is consistent with the postulated immune mode of action (MoA). Treatment-induced PD changes included an increase of proliferating and activated T cells in peripheral blood both in the single agent and combination arm. Furthermore, we observed an increased infiltration of intratumoral CD8+ and Ki67+CD8+ T cells for both treatment regimens, accompanied with the up-modulation of T cell activation genes and gene-signatures. Eleven patients experienced a complete or partial response, from which six were confirmed immune checkpoint inhibitor (CPI)-naive patients. Our results support continued evaluation of RO7122290 in combination with atezolizumab and other immuno-oncology agents.

2022-11-16 | GSE212521 | GEO

Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting

Project description:The purpose of this study is to assess the safety and efficacy of S-1 and oxaliplatin combined with radiation by Phase I/II study. The purpose of this study is as follows, * In phase I, to determine the dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD). * In phase II, to evaluate the antitumor effect (pCR rate) and the safety .

| 2097031 | ecrin-mdr-crc

miRNA expression profiles of erythroid cells following hydroxyurea treatment for sickle cell anemia

Project description:We hypothesized that miRNA regulation may be invloved in hydroxyurea-mediated fetal hemoglobin induction. Microarray analysis was utilized as an initial screening tool to determine differential miRNA expression in CD71+ erythroid cells comparing cells from control individuals without sickle cell anemia to patients with sickle cell anemia prior to treatment with hydroxyurea and patients receiving the maximum tolerated dose (MTD) of hydroxurea. CD71+ cells were isolated from whole blood of control individuals (n=2), pediatric patients without hydroxyurea treatment (n=3) and pediatric patients at hydroxyurea MTD (n=3). All 8 samples were analyzed for miRNA expression.

2011-11-21 | E-GEOD-32035 | biostudies-arrayexpress

A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer

Project description:Triplets of irinotecan, oxaliplatin and infusional 5-fluorouracil(FU)/leucovorin (LV) are associated with high response rates and long survival as first-line treatment for metastatic colorectal cancer (mCRC). The oral fluoropyrimidine, capecitabine, is better tolerated and shows better response rates than 5-FU/LV in metastatic colorectal cancer. A phase I dose-escalation study established dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended phase II doses (RPIID) of irinotecan, oxaliplatin and capecitabine. This phase I /II study is to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), phase II recommended dose (RD) of IXO and bevacizumab combination and safety at the RD in an expanded cohort.

| 2066127 | ecrin-mdr-crc

Phase I Clinical Trial of ES-285

Project description:Phase I Safety, Pharmacokinetic and Pharmacogenomic Trial of ES-285, a Novel Marine Cytotoxic Agent Administered as an Infusion over 24 h Every 21 Days in Patients with Solid Tumors Purpose: A dose-escalation, phase I study evaluated the safety, pharmacokinetics, pharmacogenomics and efficacy of ES-285, a novel agent isolated from a marine mollusc, in adult cancer patients. Experimental design: Patients received a 24-hour i.v. infusion of ES-285 once every 3 weeks until disease progression or unacceptable toxicity. The starting dose was 4mg/m2. Dose escalation proceeded according to the worst toxicity observed in the previous cohort. Results: 28 patients were treated with 72 courses of ES-285 across 8 dose levels. No doselimiting toxicities (DLTs) were seen between 4mg/m2 and 128mg/m2. Two out of 4 patients treated at 256mg/m2 had dose-limiting reversible grade 3 transaminitis; one patient at 256mg/m2 also had transient grade 3 central neurotoxicity. One of 3 patients subsequently treated at 200mg/m2 died following drug-related central neurotoxicity. Pharmacokinetic studies indicated dose-proportionality with high volume of distribution (median Vss at 256mg/m2 was 2389L, range 1615-4051L) and long elimination half life (median t1/2 at 256mg/m2 was 29h, range 21-32h). The 3 patients with DLT had the highest drug exposure. Pharmacogenomic studies of paired surrogate tissue samples identified changes in gene expression following treatment that correlated with increasing dose. Pre-treatment 59- and 49-gene sets were identified in blood and skin respectively, that may predict DLT. Disease stabilisation for 6 to 18 weeks was recorded in 9 patients. Conclusion: Using this schedule, 128 mg/m2 was considered safe and feasible. At this dose, pharmacologically relevant concentrations of drug were safely achieved with pharmacogenomic studies indicating changes in the expression of genes of potential biological relevance. Keywords: dose response

2009-04-01 | GSE12062 | GEO

Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers

Project description:Prospective non randomized, non-comparative, dose escalation, two arms open phase I trial to assess the safety and tolerability of capecitabine given in combination with aflibercept in patients with measurable or evaluable, chemorefractory digestive tumors or breast tumors in terms of the Maximum Tolerated Dose (MTD) and the Dose-Limiting Toxicities (DLTs), To establish the Recommended Phase II Dose (RP2D) of capecitabine in combination with Aflibercept.

| 2144055 | ecrin-mdr-crc

miRNA expression profiles of erythroid cells following hydroxyurea treatment for sickle cell anemia

2011-11-21 | GSE32035 | GEO

Clinical study investigating the safety PG545 in combination with nivolumab in patients with advanced solid tumours and in patients with metastatic pancreatic cancer

Project description:Interventions: Stage 1: Dose escalation in patients with advanced or metastatic solid tumours: PG545 25, 50 or 100 mg once weekly via IV infusion and Nivolumab 240 mg every two weeks via IV infusion. Patients receive weekly doses of PG545 according to the cohort to which they are assigned. A standard 3+3 cohort design is employed for each cohort. Intrasubject escalation to the next highest dose is allowed once the next highest dose has been demonstrated to be tolerated. Stage 2: Expansion phase in patients with metastatic pancreas tumour or MSS mCRC: Recommended PG545 dose from Stage 1 once weekly via IV infusion and Nivolumab 240 mg every two weeks via IV infusion. Treatment to continue until disease progression or withdrawal due to tolerability. Patients will be treated at site ensuring treatment compliance. Primary outcome(s): Stage 1: Determine the maximum tolerated dose (MTD) of once-weekly intravenously administered PG545 in combination with intravenously administered nivolumab (240 mg every two weeks) in subjects with advanced solid tumours, as defined by dose limiting toxicity. The MTD is determined using dose limiting toxicities (DLTs) assessed by the treating physician, using NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. DLT toxicities also include the development of positive anti-heparin antibody, and an inability to complete the first dosing cycle due to any toxicity thought to be associated with the test drug.[28 days post treatment commencement.];Stage 2: To assess the safety and tolerability of weekly administration of PG545 in combination with nivolumab in patients with metastatic pancreatic cancer. Outcome is assessed by clinical examination and blood tests.[Weekly for the duration of the study.] Study Design: Purpose: Treatment; Allocation: Non-randomised trial

| 2466336 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data